SymbolLMED
NameLATAMED AI CORP.
SectorUNDEFINED
RegionNorth America
Industry-
Address1071 Venezuela Av. Rómulo Gallegos con Av. Las Palmas Edif. Torre Gerencial Los Andes, Piso 4
Telephone+1 787 476 2350
Fax
Email
Websitehttps://latamed.ai
IncorporationUS
Incorporated On2008
Employees
Fiscal Year12/31
Public Since
ExchangesOTC
AuditorBlue Chip Accounting, LLC;Beckles & Company;
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0001477960
Description

LataMed AI Corp. ("LMED") is a development-stage digital health technology company focused on the design and intended commercialization of artificial intelligence-driven healthcare analytics solutions and technology-enabled medical service platforms. The Companys platform consists of an artificial intelligence-enabled healthcare analytics system and a healthcare services coordination platform designed to integrate data analytics, telehealth infrastructure, and hybrid home-based medical services. The Companys technology is intended to support clinical decision-making, patient monitoring, and care coordination through a unified digital framework. Its business strategy includes phased deployment, an initial market focus in Latin America, and expansion through strategic partnerships and regulatory approvals.

Additional info from OTC:
LataMed AI Corp. ("LMED") is a development-stage digital health technology company focused on the design and intended commercialization of artificial intelligence-driven healthcare analytics solutions and technology-enabled medical service platforms. The Companys platform consists of an artificial intelligence-enabled healthcare analytics system and a healthcare services coordination platform designed to integrate data analytics, telehealth infrastructure, and hybrid home-based medical services. The Companys technology is intended to support clinical decision-making, patient monitoring, and care coordination through a unified digital framework. Its business strategy includes phased deployment, an initial market focus in Latin America, and expansion through strategic partnerships and regulatory approvals.

No news found.